Galderma to Showcase Advanced Neuromodulator Data at TOXINS 2026
Galderma is set to reinforce its position as a global leader in injectable aesthetics with the presentation of new clinical and scientific data from its industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference, taking place in Madrid, Spain, from January 14 to 17, 2026. The company will present findings across five scientific abstracts, highlighting two of its flagship neuromodulators—Relfydess (relabotulinumtoxinA) and Dysport—while also hosting an expert-led educational masterclass dedicated to Relfydess.
TOXINS is widely regarded as one of the most important international forums for clinicians and researchers specializing in botulinum toxin science. Galderma’s strong presence at the 2026 meeting reflects its continued commitment to advancing neuromodulation science, supporting evidence-based practice, and delivering next-generation solutions that align with evolving patient and practitioner expectations.
Demonstrating leadership through innovation and science
“At TOXINS 2026, we will demonstrate our continued leadership in neuromodulation through updates on our leading portfolio and an educational session focused on Relfydess, an innovative, science-backed neuromodulator designed to deliver advanced performance,” said Baldo Scassellati Sforzolini, M.D., Ph.D., Global Head of R&D at Galderma. “As the only company with a portfolio of neuromodulators, we are building on our heritage in this space by developing solutions that respond to the changing needs of aesthetic patients and healthcare professionals.”
Galderma’s neuromodulator strategy is underpinned by end-to-end in-house capabilities, spanning discovery, clinical research, manufacturing, and global commercialization. This integrated approach enables the company to consistently bring differentiated products to market while maintaining high standards of quality, safety, and scientific rigor.
New clinical insights on Relfydess
A significant focus of Galderma’s presentations at TOXINS 2026 will be Relfydess, the first and only ready-to-use liquid neuromodulator formulated using the company’s proprietary PEARL Technology. Two of the five abstracts will feature encore post-hoc subgroup analyses derived from pooled Phase III data from the READY clinical program, evaluating treatment outcomes in patients with moderate-to-severe frown lines and crow’s feet.
These analyses demonstrated strong and consistent efficacy outcomes. Investigator-assessed responder rates exceeded 98% for frown lines and 88% for crow’s feet at one month following treatment. In addition, the median time to return to baseline severity was reported as 24 weeks for both indications, as assessed independently by patients and investigators. These findings reinforce Relfydess’ durability of effect across multiple facial areas.
Further expanding the scientific evidence base, Galderma will also present data from a new in vivo head-to-head study comparing Relfydess with onabotulinumtoxinA in a rat model. The results showed similar and limited diffusion profiles, supporting Relfydess’ targeted activity and controlled spread—an important consideration for aesthetic practitioners seeking precision and predictability in treatment outcomes.
Collectively, these data add to the growing body of evidence demonstrating Relfydess’ rapid onset of action, sustained efficacy for up to six months, robust safety profile, and high levels of patient satisfaction, regardless of prior neuromodulator treatment history.
Expert-led Relfydess Masterclass
In addition to scientific poster presentations, Galderma will host a Relfydess Masterclass at TOXINS 2026, offering attendees a deeper exploration of the product’s clinical performance and underlying science. The session will be led by renowned aesthetic experts Dr. Joanna Czuwara and Dr. Birgit Blessmann-Gurk, who will share real-world treatment experience alongside insights from clinical trials.
The masterclass will focus on Relfydess’ PEARL Technology, its rapid onset, extended duration of effect, and the scientific principles that differentiate it from traditional neuromodulators. Scheduled for January 15, from 15:50 to 16:20 CET, the session will take place in the conference’s Educational Theatre and is expected to attract strong interest from clinicians seeking to optimize neuromodulator outcomes in daily practice.
Continued evidence supporting Dysport
Galderma’s presence at TOXINS 2026 will also highlight new data supporting Dysport, one of the most established neuromodulators in the company’s portfolio. Abstracts presented at the meeting will examine patient and practitioner satisfaction with Dysport in the treatment of frown lines, including results from a real-world study conducted in China.
This study evaluated repeated Dysport treatments over three cycles and demonstrated up to 100% patient satisfaction three weeks after the third treatment cycle. The findings underscore Dysport’s consistency, reliability, and strong acceptance among patients in real-world clinical settings.
Setting the standard in neuromodulation
Galderma’s comprehensive scientific program at TOXINS 2026 highlights the breadth and depth of its neuromodulator portfolio and reinforces its leadership in this rapidly evolving field. By delivering both innovative next-generation products like Relfydess and well-established solutions such as Dysport, the company continues to meet the diverse needs of aesthetic practitioners worldwide.
With fully integrated in-house capabilities and a strong pipeline of innovation, Galderma is uniquely positioned to lead across all aspects of Injectable Aesthetics, setting new standards for performance, safety, and patient satisfaction.
More information about Galderma’s scientific presentations and activities at TOXINS 2026 is available through the conference program.
About Relfydess (relabotulinumtoxinA)
Developed and pioneered by Galderma, Relfydess is the first and only ready-to-use liquid neuromodulator formulated with PEARL Technology, designed to preserve molecular integrity. The technology delivers a highly active, complex-free molecule, with clinical studies showing effects as early as day one in up to 39% of patients, and maintained improvements for up to six months in as many as 75% of patients. Relfydess is optimized for simple volumetric dosing without reconstitution, enhancing ease of use and dosing consistency for practitioners. Created and manufactured entirely by Galderma, Relfydess has received marketing authorization in several markets, while relabotulinumtoxinA remains investigational in the United States, with authorization conditions varying internationally.
Source link :https://www.galderma.com/
